908 Devices (MASS)
Builds handheld instruments that identify hazardous chemicals at the point of need.
908 Devices Raises 2026 Outlook as Handheld Detection Demand Accelerates
908 Devices (NASDAQ: MASS) outlined its strategy to expand in handheld chemical detection following second-quarter 2026 results that showed revenue growth, a narrower adjusted EBITDA loss and increasing recurring revenue. Speaking at the Midwest IDEAS Conference, CEO and Co-Founder Kevin Knopp said the company has spent the past 18 months reshaping its operations around portable tools
908 Devices Raises 2026 Outlook as Handheld Detection Demand Accelerates
908 Devices NASDAQ: MASS outlined its strategy to expand in handheld chemical detection following second-quarter 2026 results that showed revenue growth, a narrower adjusted EBITDA loss and increasing recurring revenue.
Is 908 Devices Inc (MASS) Overvalued After 3.3% Rally? GF Value Says Overvalued
On August 21, 2026, 908 Devices Inc (MASS) shares rose 3.3% to $10.68, marking a notable increase within its 52-week range of $5.03 to $10.70. The stock has sho
TG Therapeutics Conference: 908 Devices Bets on Handheld Drug, Chemical Detection
908 Devices outlined its strategy to focus exclusively on handheld chemical and drug detection technologies for public safety and defense markets, following the divestiture of its life-sciences business line about 15 months ago.
908 Devices Eyes Growth in Handheld Drug and Chemical Detection Market
908 Devices NASDAQ: MASS is sharpening its focus on handheld chemical and drug detection systems for public safety, defense and law enforcement following the divestiture of its bioprocessing and biopharma business line, executives said during a Canaccord Genuity discussion.
908 Devices Q2: Another Solid Report
908 Devices delivered another revenue beat in Q2, as device sales continued to shine. Q2 revenues grew 23% year-over-year to $16.07 million, with product revenue up nearly 35.5% and the installed base expanding 23%. Management raised 2026 revenue guidance to $68–$70 million, implying 21–25% growth, while operating and net losses narrowed.
908 Devices: Mission Critical Devices Drive Growth
908 Devices is rated BUY after a 2Q26 earnings beat, strong revenue growth, and a 97% YTD share price gain. MASS benefits from robust demand for chemical detection devices, driven by law enforcement, defense, and volatile geopolitical conditions. Recurring revenue from NIRLab and product upgrades like VipIR underpin stable growth; management raised FY26 revenue guidance to $68–$70M.
908 Devices Inc. (MASS) Q2 2026 Earnings Call Transcript
908 Devices Inc. (MASS) Q2 2026 Earnings Call Transcript
908 Devices Q2 Earnings Call Highlights
908 Devices NASDAQ: MASS reported second-quarter revenue growth of 23% as demand from U.S. state and local government customers, FTIR product shipments and its recently acquired NIRLab platform supported results. The company also raised the low end of its full-year revenue outlook while continuing to exclude potential revenue from the U.S. military's AVCAD program from its core guidance.
908 Devices Inc. (MASS) Reports Q2 Loss, Tops Revenue Estimates
908 Devices Inc. (MASS) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to a loss of $0.18 per share a year ago.
908 Devices Reports Second Quarter 2026 Financial Results and Raises Low End of 2026 Revenue Outlook
908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety, and defense
908 Devices Reports Second Quarter 2026 Financial Results and Raises Low End of 2026 Revenue Outlook
BURLINGTON, Mass.--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety, and defense tech applications, today reported financial results for the quarter ended June 30, 2026. “We delivered another strong quarter, growing revenue 23% year-over-year, while narrowing our Adjusted EBITDA loss by more than half compared to a year ago,” said Kevin J. Knopp, CEO and Co-founder. “Our momentum.
908 Devices Inc. (MASS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
908 Devices (MASS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
908 Devices to Participate in the Canaccord Genuity 46th Annual Growth Conference
908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense
908 Devices to Participate in the Canaccord Genuity 46th Annual Growth Conference
BURLINGTON, Mass.--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech applications, announced it will participate in the upcoming Canaccord Genuity 46th Annual Growth Conference. 908 Devices' management is scheduled to present on Wednesday, August 12 at 12:30 p.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the “Inv.
908 Devices to Report Second Quarter 2026 Financial Results on August 11, 2026
BURLINGTON, Mass.--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech applications, announced it will report financial results for the second quarter 2026 before market open on Tuesday, August 11, 2026. Company management will webcast a corresponding conference call beginning at 8:30 a.m. Eastern Time. Live audio of the webcast will be available on the “Investors” s.
Masivo Confirms High-Grade Gold-Copper Mineralization Beneath Historic Boston Mine with 45 ft. of 3.25% Cu Equivalent Including 5ft.
Vancouver, British Columbia--(Newsfile Corp. - July 15, 2026) - Masivo Silver Corp. (TSXV: MASS) (OTC Pink: GNYPF) (FSE: R74) is pleased to report drill results from its Boston Mine Project in northeastern Nevada, confirming the continuation of high-grade gold, silver and copper mineralization beneath the historic underground workings. Seven drill holes were completed testing surface showings and high grade underground samples from the upper level of the mine.
Volatus Aerospace to Showcase Multi-Domain Capabilities at MASS 2026
Supporting Canada's Arctic sovereignty and maritime security through integrated, mission-ready aerospace, autonomy and intelligence solutions Supporting Canada's Arctic sovereignty and maritime security through integrated, mission-ready aerospace, autonomy and intelligence solutions
908 Devices (MASS) Upgraded to Buy: Here's Why
908 Devices (MASS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
908 Devices Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BURLINGTON, Mass.--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech applications, announced that on June 1, 2026, the Compensation Committee of its Board of Directors granted options to four new non-executive employees to purchase an aggregate of 179,912 shares of 908 Devices' common stock. The options were granted as a material inducement to employment with 908 D.